Search
for
Sort by
Research 391–420 of 1000+
- Poster Presentations
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Application of Baricitinib in Dermatology
- Cold Plasma An emerging technology for clinical use in wound healing
- Photobiomodulation therapy
- Alopecia areata following COVID-19 vaccine: a systematic review
- Autophagy: Guardian of Skin Barrier
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- The potential of Clausena anisata (Willd.) Hook.f. ex Benth against Propionibacterium acnes
- Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women
- Baricitinib for the Treatment of Alopecia Areata
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
- Immune therapies for alopecia areata: evidence and new perspectives
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Underactive bladder - an underestimated entity
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Nonscarring alopecia after temporal lifting technique with dermal fillers
- Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part III on Psychosexual Therapy and the Masculine Self-Esteem)
- In Vivo Reflectance Confocal Microscopy in General Dermatology: How to Choose the Right Indication
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases